32 articles found
Browse Rainier Rehab's editorial coverage of Clinical-research. Our writers track federal and state policy, peer-reviewed research, treatment innovations, and frontline reporting from the addiction recovery field. Each article in this collection cites primary sources — government datasets (SAMHSA, NIH, CDC), Medicaid and Medicare bulletins, JAMA and Lancet studies, and on-the-record statements from clinicians, regulators, and people in recovery — so readers can verify claims and dig deeper.
We update this tag whenever new clinical-research reporting publishes. If you're a researcher, journalist, or family member trying to make sense of substance use disorder treatment, this is the working archive. For a directory of accredited treatment facilities, visit our facilities directory; to compare modalities, see our treatments overview and levels of care guide.
University of Arkansas Medical Sciences convenes statewide summit as data reveals 60% of adolescents in substance use treatment have co-occurring mental illness.
Single dose of psilocybin with therapy support produced rapid, sustained reductions in suicidal thoughts among treatment-resistant patients
New research reveals how cAMP signaling in brain neurons drives GLP-1 weight loss effects, opening pathways to enhance addiction treatments.
University of Reading study finds single psilocybin dose reduces neuropathic pain for weeks and makes standard painkillers work better.
New real-world evidence shows extended-release buprenorphine significantly outperforms other medication-assisted treatments in preventing relapse and reducing healthcare costs.
Research published in the American Journal of Preventive Medicine reveals rising barriers to timely care for adolescents with cannabis use disorder, with younger teens and males most affected.
University of Cincinnati study demonstrates that embedding addiction treatment into primary care residency training expands patient access and boosts physician confidence in treating SUDs.
New NIH-funded research shows oral GLP-1 drugs like orforglipron reach the central amygdala, opening potential pathways for treating substance use disorders.
Despite rapid expansion of telehealth mental health services, a major JAMA study reveals only modest gains in reaching rural and underserved patients.
Forty-two addiction specialists establish consensus best practices for initiating medications for opioid use disorder in hospitals, adapting protocols for the fentanyl era.
JAMA study finds psychedelic-assisted therapy produced higher abstinence rates and longer relapse prevention than standard treatment
NIH-funded trial shows GLP-1 drug combined with cognitive behavioral therapy significantly reduces heavy drinking days in patients with alcohol use disorder and obesity.
University of Kentucky researchers find that experimental Alzheimer's medication MW150 could reduce brain inflammation and neural damage during alcohol withdrawal, potentially lowering relapse rates.
University of Chicago researchers investigate why isolation during teenage years may permanently alter brain development and increase vulnerability to substance use disorders.
New BMJ Open research finds semaglutide and tirzepatide associated with reduced alcohol-related emergency visits among adults with alcohol use disorder.
A study of 197 people who use unregulated opioids found those using cannabis to ease withdrawal had over twice the odds of reporting reduced opioid use.
A Glasgow review pooling 27 studies and 31,000 opioid-exposed children found consistent links to vision defects, ADHD-like attention problems and weaker learning.
Six patients with refractory back pain went from 9.5 to zero on the pain scale after a targeted spinal artery infusion, and two stopped opioids entirely.
A Penn State study in PNAS found opioid overdose deaths rose 26% in Appalachian counties after severe floods and stayed elevated for as long as a decade.
A University of Manchester study of 32,909 hospital patients ranked opioids by respiratory depression risk, finding fentanyl 3.36 times riskier than codeine.
A JAMA Network Open study of 11,286 US adolescents found that years of higher-than-usual problematic social media use were followed by increases in ADHD symptoms, especially in boys.
A double-blind trial found theta-burst brain stimulation cut one-year relapse risk in alcohol use disorder patients by more than half (hazard ratio 0.43).
Arizona State University researchers find opioid withdrawal suppresses two myelin-regulating genes in the prefrontal cortex, pointing to a new treatment target.
University of Maryland researcher secures federal grant to expand school-based addiction treatment access in underserved rural communities
New research from USC Keck Medicine reveals heavy marijuana smokers face 3.5 to 5 times higher risk of lung and head and neck cancers, raising questions as cannabis legalization expands.
New UNSW research shows peer workers with lived addiction experience bring unique expertise that transforms treatment outcomes and client trust.
European Heart Journal Open proposes neurocardiometabolic framework linking addiction treatment with cardiovascular care through GLP-1 receptor therapies
APA's July 2026 journal issues highlight emerging evidence for digital health tools and telehealth in treating substance use disorders in underserved communities
Imperial College London research published in Addiction journal reveals that emotional support and medical stability are key factors in successful opioid detoxification, challenging abstinence-only approaches.
NIH-funded JAMA study shows extended-release buprenorphine outperforms daily pills in pregnancy, offering new hope for maternal and infant outcomes.
UC San Diego researchers identify liver-based genetic markers for cocaine addiction, opening new avenues for medication development beyond brain-targeting approaches.
State lawmakers pass bill to study psychedelic-assisted therapy, joining growing national movement to explore alternative treatments for substance use disorders and mental health conditions.